Jan. 30 at 5:58 AM
$LXRX Those extra 86.5 on the shelf will be more than enough. And we still keep an above two dollar valuation on each share, based on the 1bil
$NVO deal as a comp, for LX9851, discounting every single other IP , pipeline we have on top of Pilavapadin.
1. Case Study = Journavx Non Opioid Pain Killer,
$VRTX had a HORRIBLE ( Nightmarish, every analyst shitted so so hard on
$VRTX, it tanked horribly with Dec Topline) Topline result, in Dec of 2024, then getting a greenlight literally a month later from the FDA (
$VRTX SOARED into the stratosphere on this unexpected FDA approval) .
2. I reiterate, their's was ONLY for moderat to Acute Pain..
$LXRX = Pilavapadin is for CHRONIC Pain, non opioid. This Administration is so anti narcotics, they'll try their damndest to put out into the market, under their administration, any pain killer, that doesn't risk causing addictions, under their watch, administration. Trump HATES substance abuse. His older brother Freddy, died of Alcohol addiction.
